Drospirenone + Ethinyl Estradiol + Levomefolate interactions
Checked as Drospirenone + Ethinylestradiol + Levomefolic acid in this data source.
Full monograph for Drospirenone + Ethinyl Estradiol + LevomefolateCheck it against another medicine
Medicines
434 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Bosentan Monohydratevia Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Coadministration with bosentan may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is bosentan induction…2 documented mechanisms | 83 sources — open the full entry |
| Brigatinibvia Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Coadministration with brigatinib may decrease the plasma concentrations of contraceptive hormones. Brigatinib has been shown in vitro to induce…2 documented mechanisms | 37 sources — open the full entry |
| Capecitabinevia Levomefolic acid | Major | Synergy | Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although… | 9 sources — open the full entry |
| Carbamazepinevia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Carfilzomibvia Drospirenone, Ethinylestradiol | Major | Synergy | Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent…2 documented mechanisms | 38 sources — open the full entry |
| Ceritinibvia Drospirenone | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by… | 9 sources — open the full entry |
| Clarithromycinvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 25 sources — open the full entry |
| Dantrolene Sodiumvia Ethinylestradiol | Major | Synergy | The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal… | 39 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycinvia Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…3 documented mechanisms | 63 sources — open the full entry |
| Fluorouracilvia Levomefolic acid | Major | Synergy | Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although… | 9 sources — open the full entry |
| Fosphenytoin Sodiumvia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Glecaprevir + Pibrentasvirvia Ethinylestradiol | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Griseofulvin [Ultra Microsize]via Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones. The proposed mechanism is accelerated clearance…2 documented mechanisms | 48 sources — open the full entry |
| Itraconazolevia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 17 sources — open the full entry |
| Ketoconazolevia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 17 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleoveravia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 17 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycinvia Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…3 documented mechanisms | 63 sources — open the full entry |
| Lenalidomidevia Drospirenone, Ethinylestradiol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 36 sources — open the full entry |
| Lopinavir + Ritonavirvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 48 sources — open the full entry |
| Mavacamtenvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with mavacamten may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is mavacamten induction…2 documented mechanisms | 1 sources — open the full entry |
| Mycophenolate Mofetilvia Drospirenone, Ethinylestradiol | Major | Others | RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The…2 documented mechanisms | 37 sources — open the full entry |
| Mycophenolic acidvia Drospirenone, Ethinylestradiol | Major | Others | RECOMMENDED: Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones. The…2 documented mechanisms | 37 sources — open the full entry |
| Nelfinavirvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 45 sources — open the full entry |
| Nirmatrelvir + Ritonavirvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…3 documented mechanisms | 57 sources — open the full entry |
| Oxcarbazepinevia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Phenobarbitalvia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Phenytoin Sodiumvia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Pomalidomidevia Drospirenone, Ethinylestradiol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1…2 documented mechanisms | 4 sources — open the full entry |
| Posaconazolevia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 17 sources — open the full entry |
| Primidonevia Levomefolic acid, Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycinvia Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…3 documented mechanisms | 63 sources — open the full entry |
| Relugolixvia Ethinylestradiol | Major | Antagonism | Coadministration of hormonal contraceptives may decrease the efficacy of the fixed-dose oral formulation of relugolix, estradiol, and norethindrone when used… | 4 sources — open the full entry |
| Relugolix + Estradiol + Norethindronevia Ethinylestradiol | Major | Antagonism | Coadministration of hormonal contraceptives may decrease the efficacy of the fixed-dose oral formulation of relugolix, estradiol, and norethindrone when used… | 4 sources — open the full entry |
| Rifampicinvia Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of…2 documented mechanisms | 113 sources — open the full entry |
| Rifampicin + Isoniazidvia Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of…3 documented mechanisms | 122 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutolvia Drospirenone, Ethinylestradiol | Major | Metabolism | RECOMMENDED: Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones. There have been numerous case reports of…3 documented mechanisms | 122 sources — open the full entry |
| Thalidomidevia Drospirenone, Ethinylestradiol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 40 sources — open the full entry |
| Tizanidine Hydrochloridevia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with oral contraceptives may significantly increase the plasma concentrations and pharmacologic effects of tizanidine. The proposed mechanism…2 documented mechanisms | 41 sources — open the full entry |
| Topiramatevia Ethinylestradiol, Drospirenone | Major | Metabolism | Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones. The…2 documented mechanisms | 56 sources — open the full entry |
| Tranexamic Acidvia Drospirenone, Ethinylestradiol | Major | Others | There are no clinical data on the use of tranexamic acid in combination with hormonal contraceptives. Because tranexamic acid is an antifibrinolytic agent…2 documented mechanisms | 38 sources — open the full entry |
| Tucatinibvia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 10 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycinvia Drospirenone, Ethinylestradiol | Major | Antagonism · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…3 documented mechanisms | 63 sources — open the full entry |
| Voriconazolevia Drospirenone, Ethinylestradiol | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms | 17 sources — open the full entry |
| Abametapirvia Drospirenone, Ethinylestradiol | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450…2 documented mechanisms | 1 sources — open the full entry |
| Acarbosevia Drospirenone, Ethinylestradiol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms | 95 sources — open the full entry |
| Acyclovir + Hydrocortisonevia Ethinylestradiol | Moderate | Synergy | Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding… | 9 sources — open the full entry |
| Adalimumabvia Drospirenone, Ethinylestradiol | Moderate | Metabolism | Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF)…2 documented mechanisms | 19 sources — open the full entry |
| Allium cepa + Heparin + Allantoinvia Drospirenone | Moderate | Synergy | The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as… | 2 sources — open the full entry |
| Alogliptin Benzoatevia Drospirenone, Ethinylestradiol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms | 95 sources — open the full entry |
| Amikacinvia Ethinylestradiol | Moderate | Antagonism | RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most… | 38 sources — open the full entry |
Food & lifestyle
grapefruit juice
ModerateMetabolism
Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.
What to do: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.
32 sources
- Edgar B, Bailey D, Bergstrand R, et al. "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7
- Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55
- Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42
- Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8
- Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4
- Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94
- Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84
- "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4
Show all 32 sourcesShow fewer sources
- Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31
- Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76
- Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395
- Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662
- Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93
- Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402
- Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9
- Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10
- Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56
- Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8
- Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83
- Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32
- Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27
- Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52
- Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38
- Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9
- Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57
- Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41
- Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58
- Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8
- Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77
- Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73
- Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8
- Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286
Conditions
Conditions in which Drospirenone + Ethinyl Estradiol + Levomefolate needs care, as documented in this source.
Hyperkalemia
MajorThe progestin drospirenone (DRSP) has antialdosterone activity, including the potential for hyperkalemia in high-risk patients. The use of DRSP-containing combination hormone is contraindicated in patients with conditions that predispose to hyperkalemia (renal impairment, hepatic impairment, and adrenal insufficiency). Use caution when prescribing these agents to women who regularly take other medications that can increase potassium, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, heparin and aldosterone antagonists. It is recommended to monitor serum potassium concentrations during the first month of dosing in high-risk patients who take strong CYP3A4 inhibitors long-term and concomitantly.
3 sources
- "Product Information. Yasmin (drospirenone-ethinyl estradiol)." Berlex Laboratories (2001):
- "Product Information. Angeliq (drospirenone-estradiol)." Berlex Laboratories (2005):
- "Product Information. Beyaz (drospirenone/ethinyl estradiol/levomefolate)." Bayer Pharmaceutical Inc (2010):
Bipolar Disorder
ModerateL-methylfolate should be used with caution in patients with a history of bipolar disorder. Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder since mood elevation in this population is possible.
1 source
- "Product Information. L-Methylfolate Calcium (l-methylfolate)." Virtus Pharmaceuticals LLC (2018):
Eye Diseases
ModerateEstrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.
13 sources
- "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
- "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
- "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
Show all 13 sourcesShow fewer sources
- "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC (2001):
- "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma (2021):
Therapeutic duplication
Drug classes that overlap with Drospirenone + Ethinyl Estradiol + Levomefolate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
estrogens
The recommended maximum number of medicines in the 'estrogens' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'estrogens' category.
Example product in the source data (US market): Oriahnn
estrogens
The recommended maximum number of medicines in the 'estrogens' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'estrogens' category.
Example product in the source data (US market): Estradiol/norethindrone/relugolix
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Hydrochlorothiazide/triamterene
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Moduretic 5-50
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Hydrochlorothiazide/spironolactone
progestins
The recommended maximum number of medicines in the 'progestins' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'progestins' category.
Example product in the source data (US market): Oriahnn